Macrophage Migration Inhibitory Factor Activates Hypoxia-inducible Factor in a P53-dependent Manner

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2008 May 22

PMID 18493321

Citations 60

Authors

Seiko Oda

Tomoyuki Oda

Kenichiro Nishi

Satoshi Takabuchi

Takuhiko Wakamatsu

Tomoharu Tanaka

Takehiko Adachi

Kazuhiko Fukuda

Gregg L Semenza

Kiichi Hirota

Affiliations

Soon will be listed here.

Abstract

Background: Macrophage migration inhibitory factor (MIF) is not only a cytokine which has a critical role in several inflammatory conditions but also has endocrine and enzymatic functions. MIF is identified as an intracellular signaling molecule and is implicated in the process of tumor progression, and also strongly enhances neovascularization. Overexpression of MIF has been observed in tumors from various organs. MIF is one of the genes induced by hypoxia in an hypoxia-inducible factor 1 (HIF-1)-dependent manner.

Methods/principal Findings: The effect of MIF on HIF-1 activity was investigated in human breast cancer MCF-7 and MDA-MB-231 cells, and osteosarcoma Saos-2 cells. We demonstrate that intracellular overexpression or extracellular administration of MIF enhances activation of HIF-1 under hypoxic conditions in MCF-7 cells. Mutagenesis analysis of MIF and knockdown of 53 demonstrates that the activation is not dependent on redox activity of MIF but on wild-type p53. We also indicate that the MIF receptor CD74 is involved in HIF-1 activation by MIF at least when MIF is administrated extracellularly.

Conclusion/significance: MIF regulates HIF-1 activity in a p53-dependent manner. In addition to MIF's potent effects on the immune system, MIF is linked to fundamental processes conferring cell proliferation, cell survival, angiogenesis, and tumor invasiveness. This functional interdependence between MIF and HIF-1alpha protein stabilization and transactivation activity provide a molecular mechanism for promotion of tumorigenesis by MIF.

Citing Articles

Exploring the role of antigen-presenting cancer-associated fibroblasts and CD74 on the pancreatic ductal adenocarcinoma tumor microenvironment.

Thomas M, Jie E, Kim A, Mayberry T, Cowan B, Luechtefeld H Med Oncol. 2024; 42(1):15.

PMID: 39585543 DOI: 10.1007/s12032-024-02564-6.

Therapeutic Opportunities in Breast Cancer by Targeting Macrophage Migration Inhibitory Factor as a Pleiotropic Cytokine.

Khezrian A, Shojaeian A, Boroujeni A, Amini R Breast Cancer (Auckl). 2024; 18:11782234241276310.

PMID: 39246383 PMC: 11380135. DOI: 10.1177/11782234241276310.

Molecular signaling and clinical implications in the human aging-cancer cycle.

Rezaeian A, Wei W Semin Cancer Biol. 2024; 106-107:28-42.

PMID: 39197809 PMC: 11625621. DOI: 10.1016/j.semcancer.2024.08.003.

TEMPI syndrome: difficult to diagnose, "easy" to treat?.

Fotiou D, Solia E, Theodorakakou F, Nikolaou P, Gakiopoulou C, Psimenou E Ann Hematol. 2024; 103(9):3787-3793.

PMID: 39078435 DOI: 10.1007/s00277-024-05893-8.

Identification of Hypoxia-ALCAM Macrophage- Exhausted T Cell Axis in Tumor Microenvironment Remodeling for Immunotherapy Resistance.

Xun Z, Zhou H, Shen M, Liu Y, Sun C, Du Y Adv Sci (Weinh). 2024; 11(33):e2309885.

PMID: 38956900 PMC: 11434037. DOI: 10.1002/advs.202309885.

References

Maxwell P, Wiesener M, Chang G, Clifford S, Vaux E, Cockman M . The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999; 399(6733):271-5. DOI: 10.1038/20459. View

Lue H, Kapurniotu A, Fingerle-Rowson G, Roger T, Leng L, Thiele M . Rapid and transient activation of the ERK MAPK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on JAB1/CSN5 and Src kinase activity. Cell Signal. 2005; 18(5):688-703. DOI: 10.1016/j.cellsig.2005.06.013. View

Wang G, Jiang B, Rue E, Semenza G . Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 1995; 92(12):5510-4. PMC: 41725. DOI: 10.1073/pnas.92.12.5510. View

Kasuno K, Takabuchi S, Fukuda K, Kizaka-Kondoh S, Yodoi J, Adachi T . Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J Biol Chem. 2003; 279(4):2550-8. DOI: 10.1074/jbc.M308197200. View

Welsh S, Williams R, Birmingham A, Newman D, Kirkpatrick D, Powis G . The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther. 2003; 2(3):235-43. View

Hudson J, Shoaibi M, Maestro R, Carnero A, Hannon G, Beach D . A proinflammatory cytokine inhibits p53 tumor suppressor activity. J Exp Med. 1999; 190(10):1375-82. PMC: 2195698. DOI: 10.1084/jem.190.10.1375. View

Bucala R, Donnelly S . Macrophage migration inhibitory factor: a probable link between inflammation and cancer. Immunity. 2007; 26(3):281-5. DOI: 10.1016/j.immuni.2007.03.005. View

Baugh J, Gantier M, Li L, Byrne A, Buckley A, Donnelly S . Dual regulation of macrophage migration inhibitory factor (MIF) expression in hypoxia by CREB and HIF-1. Biochem Biophys Res Commun. 2006; 347(4):895-903. DOI: 10.1016/j.bbrc.2006.06.148. View

Cramer T, Yamanishi Y, Clausen B, Forster I, Pawlinski R, Mackman N . HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003; 112(5):645-57. PMC: 4480774. DOI: 10.1016/s0092-8674(03)00154-5. View

10.

Brummelkamp T, Bernards R, Agami R . A system for stable expression of short interfering RNAs in mammalian cells. Science. 2002; 296(5567):550-3. DOI: 10.1126/science.1068999. View

11.

Winner M, Koong A, Rendon B, Zundel W, Mitchell R . Amplification of tumor hypoxic responses by macrophage migration inhibitory factor-dependent hypoxia-inducible factor stabilization. Cancer Res. 2007; 67(1):186-93. PMC: 2941512. DOI: 10.1158/0008-5472.CAN-06-3292. View

12.

Semenza G . Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3(10):721-32. DOI: 10.1038/nrc1187. View

13.

Semenza G . HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002; 8(4 Suppl):S62-7. DOI: 10.1016/s1471-4914(02)02317-1. View

14.

Ravi R, Mookerjee B, Bhujwalla Z, Sutter C, Artemov D, Zeng Q . Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000; 14(1):34-44. PMC: 316350. View

15.

Mitchell R, Liao H, Chesney J, Fingerle-Rowson G, Baugh J, David J . Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: regulatory role in the innate immune response. Proc Natl Acad Sci U S A. 2002; 99(1):345-50. PMC: 117563. DOI: 10.1073/pnas.012511599. View

16.

Kleemann R, Kapurniotu A, FRANK R, Gessner A, Mischke R, Flieger O . Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol. 1998; 280(1):85-102. DOI: 10.1006/jmbi.1998.1864. View

17.

Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K . Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J. 1999; 18(7):1905-14. PMC: 1171276. DOI: 10.1093/emboj/18.7.1905. View

18.

Semenza G . HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 2001; 19(1-2):59-65. DOI: 10.1023/a:1026544214667. View

19.

Karin M, Lawrence T, Nizet V . Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell. 2006; 124(4):823-35. DOI: 10.1016/j.cell.2006.02.016. View

20.

Moriguchi T, Kuroyanagi N, Yamaguchi K, Gotoh Y, Irie K, Kano T . A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3. J Biol Chem. 1996; 271(23):13675-9. DOI: 10.1074/jbc.271.23.13675. View